摘要
目的:比较用瑞舒伐他汀钙和阿托伐他汀钙对冠心病患者进行降脂治疗的效果及安全性。方法:选取某院收治的98例冠心病患者作为本次研究的对象。按照所用药物的不同将这些患者平均分为阿托伐他汀钙组和瑞舒伐他汀钙组。在这些患者入院后,对其均进行常规治疗。在此基础上,为阿托伐他汀钙组患者使用阿托伐他汀钙进行降脂治疗,为瑞舒伐他汀钙组患者使用瑞舒伐他汀钙进行降脂治疗。治疗结束后,比较两组患者在进行治疗前后其血清总胆固醇(TG)、甘油三脂(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)的水平,并比较两组患者在进行治疗期间其不良反应的发生情况。结果:进行治疗后,瑞舒伐他汀钙组患者血清TG、TC、HDL-C、LDL-C的水平及不良反应的发生率均优于阿托伐他汀钙组患者,差异有统计学意义(P<0.05)。结论:与用阿托伐他汀钙进行降脂治疗的冠心病患者相比,用瑞舒伐他汀钙进行治疗的冠心病患者其疗效更为理想,且不良反应的发生率更低。
Objective:To investigate the effect and safety of atorvastatin and atorvastatin on lipid regulation in patients with coronary heart disease.Methods:coronary heart disease received were randomly divided into control group and observation group,with 49 cases in each group.Compare the triglyceride(TC),high and low density lipoprotein cholesterol(LDL-C)changes before and after treatment.Results:the two groups of patients after a certain period of treatment were improved compared with before treatment,and the improvement of the observation group than the control group.Conclusion:the effect of simvastatin on coronary heart disease is stronger,and the incidence of adverse reaction is lower,and the effect is better.